KDM6A and breast carcinoma: Furthermore, KDM3A targeting increased response to anti-angiogenic therapies, disclosing a role in tumor angiogenesis43 Interestingly, in vitro studies in lung and breast cancer cells demonstrated that KDM6A inhibition decreased cell survival and improved RT response, through H3K27me3 enhancement44.